(Q68435561)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

title

Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

author name string

F Roila

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

S Bracarda

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

M Tonato

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

M Marangolo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

M Bella

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

D Donati

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

G Cetto

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

A Del Favero

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

publication date

1 September 1990

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

page(s)

268-272

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

Extrapyramidal reactions with metoclopramide

24 September 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

Blockade of neuronal tryptamine receptors by metoclopramide

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

Metoclopramide versus metoclopramide and lorazepam. Superiority of combined therapy in the control of cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

A prospective, randomized double-blind trial comparing metoclopramide alone with metoclopramide plus dexamethasone in preventing emesis induced by high-dose cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

Antiemetic properties of the 5HT3-receptor antagonist, GR38032F

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980953-7

7 January 2021

10.1016/S0936-6555(05)80953-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2148109%20AND%20SRC:MED&resulttype=core&format=json

24 September 2019

1 reference